TECX (Tectonic Therapeutic) Total Equity: $223.85 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TECX Tectonic Therapeutic Inc TECX
14 GF Score
Price $33.98
! 3 Warning Signs
View Full Analysis

What is Tectonic Therapeutic Total Equity?

Tectonic Therapeutic TECX -7.84% 14 Total Equity is $223.85 Mil as of Jun. 2026. GuruFocus rates TECX with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Tectonic Therapeutic's total equity for the quarter that ended in Jun. 2026 was $223.85 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Tectonic Therapeutic Total Equity Historical Data

* Premium members only.

The historical data trend for Tectonic Therapeutic's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tectonic Therapeutic Total Equity Chart

Tectonic Therapeutic Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
-14.96 -45.65 -84.64 140.78 251.33

Tectonic Therapeutic Quarterly Data
Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 283.77 267.53 251.33 230.42 223.85
TECX
14GF Score
Tectonic Therapeutic Inc TECX
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tectonic Therapeutic Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Tectonic Therapeutic's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=261.038-9.709
=251.33

Tectonic Therapeutic's Total Equity for the quarter that ended in Jun. 2026 is calculated as

Total Equity=Total Assets(Q: Jun. 2026 )-Total Liabilities(Q: Jun. 2026 )
=237.034-13.188
=223.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $223.85 Mil mean?
Tectonic Therapeutic (TECX) has a Total Equity of $223.85 Mil as of Jun. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Tectonic Therapeutic and its competitors.
Is Tectonic Therapeutic's Total Equity too high?
Tectonic Therapeutic's current Total Equity is $223.85 Mil. Overall, Tectonic Therapeutic has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Tectonic Therapeutic's Total Equity compare to ZVRA and SPRY?
Tectonic Therapeutic's Total Equity of $223.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Tectonic Therapeutic and its competitors. Tectonic Therapeutic's current Total Equity is $223.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tectonic Therapeutic stock overvalued right now?
Tectonic Therapeutic (TECX) has a current Total Equity of $223.85 Mil. The current Total Equity is $223.85 Mil. Tectonic Therapeutic's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Tectonic Therapeutic (TECX), the current Total Equity is $223.85 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tectonic Therapeutic Business Description

Address 490 Arsenal Way, Suite 210, Watertown, MA, USA, 02472
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
14GF Score

Get the complete analysis for TECX

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$33.98
Price